Skip to content
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • Ebopiprant
      • Anti-prolactin Antibody
      • XMetA Portfolio
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact
XOMA
XOMA
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Contact Us
  • Royalty Portfolio
  • Opportunities
    • Overview
    • Royalty Acquisition
    • Assets Available for Licensing
      • Phage Display Platform
      • Ebopiprant
      • Anti-prolactin Antibody
      • XMetA Portfolio
  • News
    • Company & Partner News
    • Press Releases
  • Investors
    • Overview
    • News & Events
    • Financial Information
    • Stock Data
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Contact

IRS Form 8937

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Company & Partner News
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Financial Information
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Overview
    • Charts
    • Historical Data
    • IRS Form 8937
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents

IRS Form 8937

Form 8937 Relating to Series A & Series B Cumulative Preferred Stock 2024 Four Quarterly Cash Distributions

Form 8937 Relating to Series A & Series B Cumulative Preferred Stock 2024 Four Quarterly Cash Distributions

Jan 13, 2025
Form 8937 Relating to Series A & Series B Cumulative Preferred Stock 2023 Four Quarterly Cash Distributions

Form 8937 Relating to Series A & Series B Cumulative Preferred Stock 2023 Four Quarterly Cash Distributions

Jan 11, 2024
Form 8937 Relating to Series A & Series B Cumulative Preferred Stock 2022 Four Quarterly Cash Distributions

Form 8937 Relating to Series A & Series B Cumulative Preferred Stock 2022 Four Quarterly Cash Distributions

Jan 11, 2023
Form 8937 Relating to Reverse Stock Split on October 17, 2016

Form 8937 Relating to Reverse Stock Split on October 17, 2016

Oct 31, 2016
Form 8937 Relating to Redomestication on December 31, 2011

Form 8937 Relating to Redomestication on December 31, 2011

Jan 16, 2012
RSS
  • Email Alerts
  • RSS News Feed
  • Terms of Use

© 2025 XOMA Royalty Corporation.  All rights reserved.

All references to “portfolio” on this website refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. All references to “assets” on this website refer strictly to milestone and/or royalty rights associated with individual drug product candidates in development. References to royalties or royalty rates strictly refer to future potential payment streams regardless of whether or not they are technically defined as royalties in the underlying contractual agreement; further, any rates referenced herein are subject to potential future contractual adjustments.

  • Follow us:
© 2025 XOMA • Powered by GeneratePress
Scroll back to top